Lawrence H Boise

List of Publications by Year
in descending order

246 papers	27,236 citations	22099 59 h-index	5663 162 g-index
250 all docs	250 docs citations	250 times ranked	36897 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
3	bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 1993, 74, 597-608.	13.5	2,976
4	Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death. Cell, 1995, 80, 285-291.	13.5	2,013
5	CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity, 1995, 3, 87-98.	6.6	1,099
6	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 2006, 107, 4907-4916.	0.6	992
7	Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biology, 2013, 14, 32.	3.0	885
8	Multiple Bcl-2 family members demonstrate selective dimerizations with Bax.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7834-7838.	3.3	779
9	Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9238-9242.	3.3	565
10	Bax-independent inhibition of apoptosis by Bcl-XL. Nature, 1996, 379, 554-556.	13.7	492
11	Bcl-XL and Bcl-2 repress a common pathway of cell death.. Journal of Experimental Medicine, 1995, 182, 821-828.	4.2	386
12	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications, 2018, 9, 5341.	5.8	356
13	Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells. Cancer Research, 2005, 65, 11510-11519.	0.4	292
14	bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4304-4308.	3.3	267
15	Ascorbic acid enhances arsenic trioxideâ€"induced cytotoxicity in multiple myeloma cells. Blood, 2001, 98, 805-813.	0.6	252
16	Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7350-7354.	3.3	233
17	Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage.. Genes and Development, 1996, 10, 2621-2631.	2.7	226
18	Bcl-xL can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3759-3764.	3.3	216

#	Article	IF	Citations
19	Hierarchical Control of Lymphocyte Survival. Science, 1996, 274, 67-68.	6.0	211
20	Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Current Opinion in Oncology, 2000, 12, 543-549.	1.1	210
21	Bcl-xS Antagonizes the Protective Effects of Bcl-xL. Journal of Biological Chemistry, 1996, 271, 6306-6312.	1.6	181
22	Bcl-2 and Bcl-2-Related Proteins in Apoptosis Regulation. Current Topics in Microbiology and Immunology, 1995, 200, 107-121.	0.7	168
23	Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia, 2014, 28, 690-693.	3.3	165
24	Caspase-12 and Caspase-4 Are Not Required for Caspase-dependent Endoplasmic Reticulum Stress-induced Apoptosis. Journal of Biological Chemistry, 2005, 280, 29578-29587.	1.6	156
25	Sustained antibody responses depend on CD28 function in bone marrowâ€"resident plasma cells. Journal of Experimental Medicine, 2011, 208, 1435-1446.	4.2	156
26	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 1928-1937.	0.8	148
27	The role of bcl-xL in CD40-mediated rescue from anti-Î¼-induced apoptosis in WEHI-231 B lymphoma cells. European Journal of Immunology, 1995, 25, 1352-1357.	1.6	143
28	Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5491-5495.	3.3	142
29	Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical Cancer Research, 2002, 8, 3658-68.	3.2	137
30	CD28 and apoptosis. Current Opinion in Immunology, 1995, 7, 620-625.	2.4	134
31	Integrin Î²7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood, 2011, 117, 6202-6213.	0.6	134
32	Epidermal Growth Factor Receptor-dependent Control of Keratinocyte Survival and Bcl-xL Expression through a MEK-dependent Pathway. Journal of Biological Chemistry, 2001, 276, 6320-6326.	1.6	131
33	Bortezomib-induced â€œBRCAnessâ€•sensitizes multiple myeloma cells to PARP inhibitors. Blood, 2011, 118, 6368-6379.	0.6	125
34	Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?. Trends in Microbiology, 2001, 9, 64-67.	3.5	124
35	CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood, 2007, 109, 5002-5010.	0.6	115
36	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism, 2017, 25, 358-373.	7.2	109

#	Article	IF	Citations
37	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature Communications, 2019, 10, 1911.	5.8	109
38	Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1â€“expressing myeloma cells. Blood, 2011, 118, 1329-1339.	0.6	107
39	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight, 2019, 4, .	2.3	107
40	Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia, 2016, 30, 1086-1093.	3.3	104
41	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal, 2019, 9, 94.	2.8	104
42	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in Immunology, 2019, 10, 1121.	2.2	103
43	Upstream Regulatory Role for XIAP in Receptor-Mediated Apoptosis. Molecular and Cellular Biology, 2004, 24, 7003-7014.	1.1	98
44	Cancer Metabolism and the Evasion of Apoptotic Cell Death. Cancers, 2019, 11, 1144.	1.7	98
45	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell, 2018, 34, 315-330.e7.	7.7	94
46	CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis. Journal of Immunology, 2000, 165, 5105-5111.	0.4	92
47	Ricolinostat (<scp>ACY</scp>â€1215) induced inhibition of aggresome formation accelerates carfilzomibâ€induced multiple myeloma cell death. British Journal of Haematology, 2015, 169, 423-434.	1.2	89
48	Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-Î°B. Blood, 2003, 101, 2321-2327.	0.6	87
49	Bone marrow microenvironmentâ€“derived signals induce Mcl-1 dependence in multiple myeloma. Blood, 2017, 129, 1969-1979.	0.6	85
50	CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment. Journal of Immunology, 2011, 187, 1243-1253.	0.4	84
51	CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood, 2014, 123, 3770-3779.	0.6	79
52	How I treat high-risk myeloma. Blood, 2015, 126, 1536-1543.	0.6	77
53	Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene, 2016, 35, 3955-3964.	2.6	76
54	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of reâ€treatment with daratumumab among refractory patients. Cancer, 2019, 125, 2991-3000.	2.0	73

#	Article	IF	Citations
55	BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxideâ€“induced cell death in myeloma. Blood, 2008, 111, 5152-5162.	0.6	72
56	The prodomain of caspase-3 regulates its own removal and caspase activation. Cell Death Discovery, 2019, 5, 56.	2.0	70
57	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature Communications, 2021, 12, 1714.	5.8	70
58	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. Nucleic Acids Research, 2017, 45, 2396-2407.	6.5	69
59	Regulation of T Cell Activation by CD28 and CTLA4. Advances in Experimental Medicine and Biology, 1996, 406, 209-217.	0.8	69
60	Loss of the Bcl-2 Phosphorylation Loop Domain Increases Resistance of Human Leukemia Cells (U937) to Paclitaxel-Mediated Mitochondrial Dysfunction and Apoptosis. Biochemical and Biophysical Research Communications, 1999, 259, 67-72.	1.0	65
61	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood, 2014, 123, 3269-3276.	0.6	64
62	Targeting <scp>BCL</scp>â€2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology, 2021, 96, 418-427.	2.0	64
63	Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene, 2001, 20, 7029-7040.	2.6	62
64	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature Communications, 2020, 11, 1228.	5.8	62
65	The Tao of myeloma. Blood, 2014, 124, 1873-1879.	0.6	60
66	Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts. Journal of Lipid Research, 2014, 55, 1298-1309.	2.0	58
67	KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood, 2012, 119, 1450-1458.	0.6	56
68	CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. Journal of Immunology, 2015, 194, 4717-4728.	0.4	56
69	Apoptosis Induced by Differentiation or Serum Deprivation in an Immortalized Central Nervous System Neuronal Cell Line. Journal of Neurochemistry, 2002, 67, 1908-1920.	2.1	55
70	Role of Cytochrome c in Apoptosis: Increased Sensitivity to Tumor Necrosis Factor Alpha Is Associated with Respiratory Defects but Not with Lack of Cytochrome c Release. Molecular and Cellular Biology, 2007, 27, 1771-1783.	1.1	54
71	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports, 2021, 34, 108532.	2.9	54
72	Mitochondria as targets for established and novel anti-cancer agents. Drug Resistance Updates, 2001, 4, 85-91.	6.5	52

#	Article	IF	Citations
73	Bcl-xL Inhibits Cytochrome c Release but Not Mitochondrial Depolarization during the Activation of Multiple Death Pathways by Tumor Necrosis Factor-Î±. Journal of Biological Chemistry, 2000, 275, 31546-31553.	1.6	50
74	Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Molecular Cancer Therapeutics, 2009, 8, 1197-1206.	1.9	49
75	Discovery and biological characterization of potent myeloid cell leukemiaâ€1 inhibitors. FEBS Letters, 2017, 591, 240-251.	1.3	49
76	Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia, 1999, 13, 1564-1573.	3.3	47
77	Bcl-xL Protein Protects from C/EBP Homologous Protein (CHOP)-dependent Apoptosis during Plasma Cell Differentiation. Journal of Biological Chemistry, 2014, 289, 23629-23640.	1.6	47
78	Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Molecular Cancer Therapeutics, 2003, 2, 1155-64.	1.9	47
79	Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. Oncogene, 2005, 24, 6354-6366.	2.6	45
80	Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia, 2009, 23, 2181-2183.	3.3	45
81	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood, 2021, 137, 3604-3615.	0.6	44
82	Regulation of RelB Expression during the Initiation of Dendritic Cell Differentiation. Molecular and Cellular Biology, 2005, 25, 7900-7916.	1.1	43
83	Protein Kinase C Î²II Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression. Journal of Biological Chemistry, 2005, 280, 28412-28423.	1.6	43
84	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Molecular Cancer Research, 2015, 13, 1163-1173.	1.5	43
85	Potentiation of 1-Î²-d-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochemical Pharmacology, 2000, 60, 1445-1456.	2.0	41
86	Elevated expression of Bcl-2 and Bcl-x by intestinal intraepithelial lymphocytes: resistance to apoptosis by glucocorticoids and irradiation. International Immunology, 1997, 9, 945-953.	1.8	40
87	Bcl-2 and Caspase Inhibition Cooperate to Inhibit Tumor Necrosis Factor-Î±-induced Cell Death in a Bcl-2 Cleavage-independent Fashion. Journal of Biological Chemistry, 1999, 274, 18552-18558.	1.6	39
88	Speciation, formation, stability and analytical challenges of human arsenic metabolites. Journal of Analytical Atomic Spectrometry, 2009, 24, 1397.	1.6	39
89	Arsenic Trioxide in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2002, 8, 12-25.	1.0	37
90	Bortezomibâ€containing induction regimens in transplantâ€eligible myeloma patients. Cancer, 2013, 119, 4119-4128.	2.0	36

#	Article	IF	Citations
91	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia, 2019, 33, 1291-1296.	3.3	36
92	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	2.0	36
93	Reactive Oxygen Species Are Not Required for an Arsenic Trioxide-induced Antioxidant Response or Apoptosis. Journal of Biological Chemistry, 2009, 284, 12886-12895.	1.6	34
94	TGF-Î² causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 2020, 10, 7656-7670.	4.6	34
95	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget, 2016, 7, 59727-59741.	0.8	33
96	CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. Cell Reports, 2020, 31, 107815.	2.9	32
97	R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Molecular Cancer Therapeutics, 2004, 3, 179-86.	1.9	32
98	Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1009-1010, 55-65.	1.2	29
99	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. Journal of Biological Chemistry, 2017, 292, 10142-10152.	1.6	28
100	Procaspase-3 regulates fibronectin secretion and influences adhesion, migration and survival independent of catalytic function. Journal of Cell Science, 2014, 127, 2217-26.	1.2	27
101	Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood, 2010, 116, 5285-5288.	0.6	25
102	Game of Bones: How Myeloma Manipulates Its Microenvironment. Frontiers in Oncology, 2020, 10, 625199.	1.3	24
103	Receptors That Regulate T-Cell Susceptibility to Apoptotic Cell Death. Annals of the New York Academy of Sciences, 1995, 766, 70-80.	1.8	21
104	Dimethylarsinothioyl Glutathione as a Metabolite in Human Multiple Myeloma Cell Lines upon Exposure to Darinaparsin. Chemical Research in Toxicology, 2014, 27, 754-764.	1.7	21
105	Integrated Analysis of Whole-Genome Paired-End and Mate-Pair Sequencing Data for Identifying Genomic Structural Variations in Multiple Myeloma. Cancer Informatics, 2014, 13s2, CIN.S13783.	0.9	20
106	Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells. Leukemia and Lymphoma, 2003, 44, 2123-2134.	0.6	19
107	N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leukemia and Lymphoma, 2005, 46, 899-908.	0.6	19
108	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Advances, 2019, 3, 3214-3227.	2.5	19

#	Article	IF	Citations
109	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget, 2016, 7, 27753-27763.	0.8	19
110	High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemotherapy and Pharmacology, 2010, 66, 129-140.	1.1	18
111	A MCP1 fusokine with CCR2-specific tumoricidal activity. Molecular Cancer, 2011, 10, 121.	7.9	18
112	Phosphorylation alters Bimâ€mediated Mclâ€1 stabilization and priming. FEBS Journal, 2018, 285, 2626-2640.	2.2	18
113	Interleukin 2â€"mediated Uncoupling of T Cell Receptor Î±/Î² from CD3 Signaling. Journal of Experimental Medicine, 1998, 188, 1575-1586.	4.2	17
114	Chromosome instability in diffuse large <scp>B</scp> cell lymphomas is suppressed by activation of the noncanonical <scp>NF</scp>â€Îº<scp>B</scp> pathway. International Journal of Cancer, 2015, 136, 2341-2351.	2.3	17
115	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biology and Therapy, 2016, 17, 769-777.	1.5	17
116	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene, 2017, 36, 4224-4232.	2.6	17
117	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 926-926.	0.6	17
118	In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-Î²-d-arabinofuranosylcytosine in human leukemia cells. Biochemical Pharmacology, 1991, 42, 853-867.	2.0	16
119	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 332-344.	0.2	16
120	Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. Journal of Clinical Immunology, 1997, 17, 234-246.	2.0	15
121	CD86 regulates myeloma cell survival. Blood Advances, 2017, 1, 2307-2319.	2.5	15
122	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	2.8	15
123	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 3178-3189.	3.2	15
124	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	2.6	15
125	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers, 2021, 13, 4787.	1.7	14
126	Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in WaldenstrÃ¶m macroglobulinemia. Oncogene, 2016, 35, 479-490.	2.6	13

#	Article	IF	Citations
127	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. Blood, 2014, 124, 2139-2139.	0.6	13
128	Extraction tool and matrix effects on arsenic speciation analysis in cell lines. Analytica Chimica Acta, 2011, 699, 187-192.	2.6	12
129	14-3-3Î¶ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia, 2018, 32, 744-751.	3.3	12
130	BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 11-24.	1.2	12
131	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. Nucleic Acids Research, 2016, 44, e69-e69.	6.5	11
132	Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma. Cancer Research, 2019, 79, 2102-2103.	0.4	11
133	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3282-3282.	0.6	11
134	Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients. Blood, 2019, 134, 572-572.	0.6	11
135	Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquisition of Arsenic Trioxide Resistance in Multiple Myeloma. PLoS ONE, 2012, 7, e52662.	1.1	11
136	Introduction of the cell survival gene bcl-xL improves the viability of CTLL-2 cells without affecting their IL-2 proliferative response Implications for the development of bioassays. Journal of Immunological Methods, 1996, 191, 143-148.	0.6	10
137	Components of intrinsic drug resistance in the rat hepatoma. Biochemical Pharmacology, 1992, 43, 331-342.	2.0	8
138	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of Oncology Practice, 2018, 14, 561-564.	2.5	8
139	Oncolytic herpes simplex virus infects myeloma cells inÂvitro and inÂvivo. Molecular Therapy - Oncolytics, 2021, 20, 519-531.	2.0	8
140	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. Blood, 2013, 122, 3135-3135.	0.6	8
141	The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leukemia Research, 2012, 36, 784-790.	0.4	7
142	Downregulation of PA28Î± induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal, 2020, 10, 125.	2.8	7
143	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American Journal of Hematology, 2021, 96, E68-E71.	2.0	7
144	Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[Î²-D-arabinofuranosyl]cytosine-induced apoptosis. Cell Death and Differentiation, 1997, 4, 294-303.	5.0	6

#	Article	IF	Citations
145	The Future of Drug Development and Therapy in Myeloma. Seminars in Oncology, 2013, 40, 652-658.	0.8	6
146	Potential application of SERS for arsenic speciation in biological matrices. Analytical and Bioanalytical Chemistry, 2017, 409, 4683-4695.	1.9	6
147	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. Blood, 2018, 132, 952-952.	0.6	6
148	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. Blood, 2009, 114, 1689-1689.	0.6	6
149	Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells. Blood, 2011, 118, 182-182.	0.6	6
150	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: Synergy for all the right reasons. Autophagy, 2011, 7, 448-449.	4.3	5
151	DUB-ling down on B-cell malignancies. Blood, 2015, 125, 3522-3523.	0.6	5
152	BCL2 dependency in diffuse large B-cell lymphoma: itâ€™s a family affair. Haematologica, 2020, 105, 1993-1996.	1.7	5
153	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. Blood, 2011, 118, 3994-3994.	0.6	5
154	Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer, 2019, 125, 185-193.	2.0	4
155	Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma. Blood, 2019, 134, 4407-4407.	0.6	4
156	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. Blood, 2011, 118, 1855-1855.	0.6	4
157	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. Oncology, 2011, 25 Suppl 2, 25-31.	0.4	4
158	Chapter 2 Cloning and analysis of Bcl-2 family genes. Methods in Cell Biology, 2001, 66, 29-47.	0.5	3
159	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 5647-5647.	0.6	3
160	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. Blood, 2006, 108, 1966-1966.	0.6	3
161	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. Blood, 2012, 120, 2072-2072.	0.6	3
162	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. Blood, 2018, 132, 405-405.	0.6	3

#	Article	IF	Citations
163	PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival. Molecular Cancer Research, 2022, 20, 1122-1136.	1.5	3
164	Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers, 2022, 14, 2228.	1.7	3
165	Î² adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica, 2022, 107, 2226-2231.	1.7	3
166	Aiming at WM with both barrels blocked. Blood, 2010, 115, 4007-4008.	0.6	2
167	Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e22-e23.	0.2	2
168	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2018, 132, 3294-3294.	0.6	2
169	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. Blood, 2013, 122, 1924-1924.	0.6	2
170	Efficacy Of ABT-199 In Multiple Myeloma. Blood, 2013, 122, 4453-4453.	0.6	2
171	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). Blood, 2015, 126, 5344-5344.	0.6	2
172	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. Blood, 2016, 128, 2108-2108.	0.6	2
173	Bcl-xL Protects From UPR-Associated Apoptosis During Plasma Cell Differentiation. Blood, 2012, 120, 3288-3288.	0.6	2
174	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. Blood, 2018, 132, 951-951.	0.6	2
175	Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease. Blood, 2019, 134, 858-858.	0.6	2
176	To Gli or not to Gli. Blood, 2014, 124, 2008-2009.	0.6	1
177	TG02 inhibits proteasome inhibitorâ€"induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood Advances, 2017, 1, 1848-1853.	2.5	1
178	A miRaculous new therapy in myeloma?. Blood, 2018, 132, 983-985.	0.6	1
179	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2018, 132, 3241-3241.	0.6	1
180	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. Blood, 2018, 132, 1884-1884.	0.6	1

#	Article	IF	Citations
181	In Vitro Activity of a Novel Organic Arsenical (S-Dimethylarsino-Glutathione, ZIO-101) Against Multiple Myeloma.. Blood, 2005, 106, 5163-5163.	0.6	1
182	Targeting the CD28-B7 Pro-Survival Pathway In Multiple Myeloma. Blood, 2010, 116, 132-132.	0.6	1
183	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. Blood, 2012, 120, 4289-4289.	0.6	1
184	Mir-155 Expression Raises the Apoptotic Threshold in WaldenstrÃ¶m Macroglobulinemia By Inhibition of FOXO3a and Bim. Blood, 2014, 124, 1671-1671.	0.6	1
185	Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Blood, 2014, 124, 5773-5773.	0.6	1
186	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology, 2013, 31, 8540-8540.	0.8	1
187	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. Blood, 2011, 118, 3950-3950.	0.6	1
188	Targeting the Cellular and Molecular Components of CD28 Mediated Survival Signaling in Multiple Myeloma. Blood, 2012, 120, 722-722.	0.6	1
189	Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma. Blood, 2013, 122, 4446-4446.	0.6	1
190	Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells. Scientific World Journal, The, 2001, 1, 110-110.	0.8	0
191	Conversion from a Type I to a Type II Death Receptor-Mediated Pathway through A Partial Inhibition of Caspase-8. Scientific World Journal, The, 2001, 1, 98-98.	0.8	0
192	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy, 2013, , 41.	1.2	0
193	Combined Targeting of Mcl-1 With TG02 and Bcl-2 With ABT-199/ABT-737 for Treatment of Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S152.	0.2	0
194	Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e68-e69.	0.2	0
195	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S250-S251.	0.2	0
196	Myelomaâ€™s sound of silencing. Blood, 2019, 134, 1116-1117.	0.6	0
197	CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e48-e49.	0.2	0
198	CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.. Blood, 2005, 106, 355-355.	0.6	0

#	Article	IF	Citations
199	Glutathione and Glutathione Utilizing Enzymes Are Key Determinants in the Sensitivity of Myeloma Cells to Arsenic Trioxide as Well as Its Mechanism of Action.. Blood, 2005, 106, 5143-5143.	0.6	0
200	Gene Profile during Arsenic Trioxide-Induced Apoptosis in Multiple Myeloma: Strong Anti-Oxidantive Response and Pro-Apoptotic Imbalance.. Blood, 2005, 106, 5175-5175.	0.6	0
201	S-Dimethylarsinoglutathione (SGLU/ZIO101) Is a Novel Active Organic Arsenical That Displays a Unique Gene Expression Profile in Myeloma Cells.. Blood, 2006, 108, 5043-5043.	0.6	0
202	Arsenic Trioxide Induces Up-Regulation of BMF and NOXA and Overcomes an Anti-Oxidative Response To Induce Apoptosis in Myeloma Cells.. Blood, 2006, 108, 3419-3419.	0.6	0
203	Bak Binding to Bcl-xL and Not to Mcl-1 Is Associated with ABT-737 Sensitivity in Multiple Myeloma Cell Lines. Blood, 2008, 112, 3675-3675.	0.6	0
204	Displacement of Bim From Anti-Apoptotic Proteins Is the Primary Factor for Determining ABT-737 Activity in Multiple Myeloma Cell Lines.. Blood, 2009, 114, 2851-2851.	0.6	0
205	Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-xL/BCL-2 In Multiple Myeloma. Blood, 2010, 116, 4054-4054.	0.6	0
206	Long Term Humoral Immunity Is Dependent on CD28 Expression In Plasma Cells. Blood, 2010, 116, 1737-1737.	0.6	0
207	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials,. Blood, 2011, 118, 3954-3954.	0.6	0
208	Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment. Blood, 2011, 118, 473-473.	0.6	0
209	Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. Blood, 2011, 118, 2891-2891.	0.6	0
210	ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma. Blood, 2011, 118, 2884-2884.	0.6	0
211	Validation of the Function of 14-3-3 Î¶ in Multiple Myeloma (MM). Blood, 2011, 118, 1369-1369.	0.6	0
212	MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells. Blood, 2011, 118, 1870-1870.	0.6	0
213	Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.. Blood, 2012, 120, 2953-2953.	0.6	0
214	CD28 and CD86 Are Necessary for Myeloma Cell Survival.. Blood, 2012, 120, 2946-2946.	0.6	0
215	Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma. Blood, 2012, 120, 3974-3974.	0.6	0
216	Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. Blood, 2012, 120, 4024-4024.	0.6	0

#	Article	IF	Citations
217	TGR-1202: A Novel, Targeted PI3KÎ´ Inhibitor in Multiple Myeloma. Blood, 2012, 120, 5018-5018.	0.6	0
218	The Role of 14-3-3Î¶ in Regulation of Proteasome Inhibitor Bortezomib Sensitivity in Multiple Myeloma. Blood, 2012, 120, 1845-1845.	0.6	0
219	CD28 and CD86 Regulate Integrin Surface Expression In Multiple Myeloma. Blood, 2013, 122, 4450-4450.	0.6	0
220	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). Blood, 2013, 122, 5606-5606.	0.6	0
221	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. Blood, 2013, 122, 5582-5582.	0.6	0
222	Combined Carfilzomib and Selective PI3KÎ´ Inhibition (TGR1202) Results In Enhanced Myeloma Cell Apoptosis. Blood, 2013, 122, 3224-3224.	0.6	0
223	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. Blood, 2013, 122, 1929-1929.	0.6	0
224	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). Blood, 2013, 122, 3148-3148.	0.6	0
225	Heterogeneous Bcl-2 Family Expression In WaldenstrÃ¶m Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis. Blood, 2013, 122, 4287-4287.	0.6	0
226	Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. Blood, 2013, 122, 3171-3171.	0.6	0
227	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. Blood, 2013, 122, 1856-1856.	0.6	0
228	Detection of NFKB2 3â€™end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma. Blood, 2014, 124, 2138-2138.	0.6	0
229	Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. Blood, 2014, 124, 3447-3447.	0.6	0
230	Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. Blood, 2014, 124, 2604-2604.	0.6	0
231	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. Blood, 2014, 124, 4726-4726.	0.6	0
232	Induction of Bim-Dependent and -Independent Apoptosis in Multiple Myeloma. Blood, 2014, 124, 4716-4716.	0.6	0
233	Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). Blood, 2015, 126, 4202-4202.	0.6	0
234	Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy. Blood, 2015, 126, 2049-2049.	0.6	0

#	Article	IF	Citations
235	Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. Blood, 2016, 128, 4524-4524.	0.6	0
236	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	0.6	0
237	Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival. Blood, 2018, 132, 3174-3174.	0.6	0
238	A Role for Syntenin-1 in Multiple Myeloma Cell Survival. Blood, 2018, 132, 1008-1008.	0.6	0
239	The Role of Proteasome Activator PA28Î± in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	0.6	0
240	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins. Blood, 2019, 134, 318-318.	0.6	0
241	P-073: PDZ proteins, SCRIB and DLG1, regulate CD86 surface expression, myeloma growth, and survival. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S79.	0.2	0
242	Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma. Blood, 2021, 138, 1612-1612.	0.6	0
243	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	0.6	0
244	Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma. Blood, 2021, 138, 1589-1589.	0.6	0
245	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. Blood, 2021, 138, 1611-1611.	0.6	0
246	Agent myeloma has a new weapon from (ch1)Q. Blood, 2022, 139, 1927-1928.	0.6	0